.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Healthtrust
Farmers Insurance
Baxter
Mallinckrodt
Citi
Teva
Chubb
Chinese Patent Office
Johnson and Johnson

Generated: September 24, 2017

DrugPatentWatch Database Preview

Patents Expiring in April 2026

« Back to Dashboard
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pernix Ireland Ltd
TREXIMET
naproxen sodium; sumatriptan succinate
TABLET;ORAL021926-001Apr 15, 2008RXYesYes► Subscribe► SubscribeY
Pernix Ireland Ltd
TREXIMET
naproxen sodium; sumatriptan succinate
TABLET;ORAL021926-002May 14, 2015RXYesNo► Subscribe► SubscribeY
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY
Glaxosmithkline Cons
FLONASE SENSIMIST ALLERGY RELIEF
fluticasone furoate
SPRAY, METERED;NASAL022051-002Aug 2, 2016OTCYesYes► Subscribe► SubscribeY
Neos Theraps
ADZENYS XR-ODT
amphetamine
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-006Jan 27, 2016RXYesYes► Subscribe► SubscribeY
Neos Theraps
ADZENYS XR-ODT
amphetamine
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-005Jan 27, 2016RXYesNo► Subscribe► SubscribeY
Neos Theraps
ADZENYS XR-ODT
amphetamine
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-004Jan 27, 2016RXYesNo► Subscribe► SubscribeY
Neos Theraps
ADZENYS XR-ODT
amphetamine
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-003Jan 27, 2016RXYesNo► Subscribe► SubscribeY
Neos Theraps
ADZENYS XR-ODT
amphetamine
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-002Jan 27, 2016RXYesNo► Subscribe► SubscribeY
Neos Theraps
ADZENYS XR-ODT
amphetamine
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-001Jan 27, 2016RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Julphar
QuintilesIMS
Daiichi Sankyo
Farmers Insurance
Johnson and Johnson
Harvard Business School
Dow
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot